Literature DB >> 27488176

Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy.

Niclas Eriksson1, Lars Wallentin1, Lars Berglund1, Tomas Axelsson2, Stuart Connolly3, John Eikelboom3, Michael Ezekowitz4, Jonas Oldgren1, Guillaume Paré3, Paul Reilly5, Agneta Siegbahn2, Ann-Christine Syvanen2, Claes Wadelius6, Salim Yusuf3, Mia Wadelius2.   

Abstract

AIMS: We investigated associations between genetic variation in candidate genes and on a genome-wide scale with warfarin maintenance dose, time in therapeutic range (TTR), and risk of major bleeding. MATERIALS &
METHODS: In total, 982 warfarin-treated patients from the RE-LY trial were studied.
RESULTS: After adjusting for SNPs in VKORC1 and CYP2C9, SNPs in DDHD1 (rs17126068) and NEDD4 (rs2288344) were associated with dose. Adding these SNPs and CYP4F2 (rs2108622) to a base model increased R(2) by 2.9%. An SNP in ASPH (rs4379440) was associated with TTR (-6.8% per minor allele). VKORC1 was associated with time less than INR 2.0. VKORC1 and CYP2C9 were associated with time more than INR 3.0, but not with major bleeding.
CONCLUSIONS: We identified two novel genes associated with warfarin maintenance dose and one gene associated with TTR. These genes need to be replicated in an independent cohort.

Entities:  

Keywords:  CYP2C9; CYP4F2; VKORC1; genome-wide association study; prediction models; time in therapeutic range; warfarin; warfarin dose

Mesh:

Substances:

Year:  2016        PMID: 27488176     DOI: 10.2217/pgs-2016-0061

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  11 in total

1.  The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.

Authors:  Ari Allyn-Feuer; Alex Ade; Jasmine A Luzum; Gerald A Higgins; Brian D Athey
Journal:  Pharmacogenomics       Date:  2018-02-05       Impact factor: 2.533

2.  CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.

Authors:  Elizaveta Panchenko; Ekaterina Kropacheva; Anatoly Dobrovolsky; Elena Titaeva; Oksana Zemlyanskaya; Dmitry Trofimov; Irina Galkina; Galina Lifshits; Natalya Vereina; Sergey Sinitsin; Nadezda Vorobyeva; Lyudmila Grehova; Dmitry Zateyshchikov; Irina Zotova; Tatyana Vavilova; Olga Sirotkina; Alevtina Grontkovskaya
Journal:  Pharmacogenomics J       Date:  2020-02-06       Impact factor: 3.550

Review 3.  Precision dosing of warfarin: open questions and strategies.

Authors:  Xi Li; Dan Li; Ji-Chu Wu; Zhao-Qian Liu; Hong-Hao Zhou; Ji-Ye Yin
Journal:  Pharmacogenomics J       Date:  2019-02-12       Impact factor: 3.550

4.  The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation.

Authors:  Pascal Vranckx; Marco Valgimigli; Hein Heidbuchel
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-03

5.  Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.

Authors:  Nianjun Liu; Marguerite R Irvin; Degui Zhi; Amit Patki; T Mark Beasley; Deborah A Nickerson; Charles E Hill; Jinbo Chen; Stephen E Kimmel; Nita A Limdi
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

Review 6.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

7.  Identification of environmental and genetic factors that influence warfarin time in therapeutic range.

Authors:  Mariana R Botton; Patrícia P Viola; Mariana R Meireles; Estela M Bruxel; Priccila Zuchinali; Eliane Bandinelli; Luis E Rohde; Tiago L L Leiria; Joyce Y Y Salamoni; Arthur P Garbin; Mara H Hutz
Journal:  Genet Mol Biol       Date:  2020-02-10       Impact factor: 1.771

8.  Impact of PCSK9, WDR12, CDKN2A, and CXCL12 Polymorphisms in Jordanian Cardiovascular Patients on Warfarin Responsiveness and Sensitivity.

Authors:  Rasheed K Ibdah; Laith N Al-Eitan; Nasr N Alrabadi; Ayah Y Almasri; Adan H Alnaamneh; Rame H Khasawneh; Mansour A Alghamdi
Journal:  Int J Gen Med       Date:  2021-01-14

Review 9.  Cardiovascular Pharmacogenomics: An Update on Clinical Studies of Antithrombotic Drugs in Brazilian Patients.

Authors:  Thiago Dominguez Crespo Hirata; Carolina Dagli-Hernandez; Fabiana Dalla Vecchia Genvigir; Volker Martin Lauschke; Yitian Zhou; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Mol Diagn Ther       Date:  2021-08-06       Impact factor: 4.074

Review 10.  Pharmacogenetic studies with oral anticoagulants. Genome-wide association studies in vitamin K antagonist and direct oral anticoagulants.

Authors:  Natalia Cullell; Caty Carrera; Elena Muiño; Nuria Torres; Jerzy Krupinski; Israel Fernandez-Cadenas
Journal:  Oncotarget       Date:  2018-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.